Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    TETRA Technologies Inc.

    NYSE: TTI · Real-Time Price · USD
    3.96
    0.04 (1.15%)
    At close: Aug 14, 2025, 3:59 PM
    3.96
    0.00%
    After-hours: Aug 14, 2025, 07:58 PM EDT
    1.15%
    Bid 3.92
    Market Cap 527.79M
    Revenue (ttm) 607.22M
    Net Income (ttm) 115.08M
    EPS (ttm) 0.92
    PE Ratio (ttm) 4.3
    Forward PE 13.43
    Analyst Strong Buy
    Ask 3.96
    Volume 1,011,423
    Avg. Volume (20D) 1,972,593.4
    Open 3.92
    Previous Close 3.92
    Day's Range 3.82 - 3.97
    52-Week Range 2.03 - 5.12
    Beta 1.34

    About TTI

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol TTI
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for TTI stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    TETRA Technologies Inc. is scheduled to release its earnings on Oct 28, 2025, after market closes.
    Analysts project revenue of ... Unlock content with Pro Subscription
    2 months ago
    +18.93%
    Shares of energy stocks are trading higher amid a ... Unlock content with Pro Subscription
    3 months ago
    +3.26%
    TTI stock has given up its prior gain. Tetra Technologies shares were trading higher following a Q1 adjusted EPS beat.
    news image

    1 week ago · benzinga.com

    Top 2 Energy Stocks That May Fall Off A Cliff This Quarter

    As of Aug. 1, 2025, two stocks in the energy sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

    news image

    2 weeks ago · seekingalpha.com

    TETRA Technologies, Inc. (TTI) Q2 2025 Earnings Call Transcript

    TETRA Technologies, Inc. (NYSE:TTI ) Q2 2025 Earnings Conference Call July 30, 2025 10:30 AM ET Company Participants Brady M. Murphy - President, CEO & Director Elijio V.

    news image

    2 weeks ago · zacks.com

    Tetra Technologies (TTI) Q2 Earnings Match Estimates

    Tetra Technologies (TTI) came out with quarterly earnings of $0.09 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.07 per share a year ago.

    news image

    1 month ago · newsfilecorp.com

    Thiogenesis Receives Confirmatory Guidance on IMPD for Pediatric MASH Phase 2a Clinical Trial in Europe and Core Patent Granted in EU

    San Diego, California--(Newsfile Corp. - June 25, 2025) - Thiogenesis Therapeutics, Inc. (TSXV: TTI) (OTCQX: TTIPF), a clinical-stage biopharmaceutical company developing next-generation thiol-based t...

    news image

    1 month ago · newsfilecorp.com

    Thiogenesis Therapeutics to Present at UMDF's Mitochondrial Medicine 2025 Conference

    Dr. Rioux to Highlight Industry-Leading Clinical Programs in MELAS and Leigh Syndrome Spectrum San Diego, California--(Newsfile Corp. - June 20, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OT...

    news image

    1 month ago · newsfilecorp.com

    Thiogenesis Announces Second Site Begins Enrolling in Phase 2 MELAS Clinical Trial and Provides Update

    San Diego, California--(Newsfile Corp. - June 17, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biopharmaceutical company develop...

    news image

    2 months ago · newsfilecorp.com

    Thiogenesis Announces Grant of Stock Options

    San Diego, California--(Newsfile Corp. - June 12, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing ...

    news image

    2 months ago · newsfilecorp.com

    Thiogenesis Announces FDA Clearance of its Investigational New Drug Application ("IND") for a Phase 2a Clinical Trial in Leigh Syndrome Spectrum

    San Diego, California--(Newsfile Corp. - June 11, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ('Thiogenesis' or the 'Company') a clinical-stage biotechnology company developing ...

    news image

    2 months ago · businesswire.com

    Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis

    HOUSTON--(BUSINESS WIRE)-- #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, smal...

    Add to Watchlist